Patricia Delaite

Director/Board Member at CANTARGIA AB

61 year

Health Technology

Consumer Services

Profile

Patricia Delaite is an Independent Director at Cantargia AB since 2017.
Prior to this, she worked as the Chief Medical Officer at Amal Therapeutics SA and Nouscom AG.
She holds a doctorate degree from the University of Geneva and an MBA from the University of Lausanne.

Patricia Delaite active positions

Companies	Position	Start
CANTARGIA AB	Director/Board Member	31/12/2016

All active positions of Patricia Delaite

Former positions of Patricia Delaite

Companies	Position	End
Nouscom AG Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.	Chief Tech/Sci/R&D Officer	-
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Chief Tech/Sci/R&D Officer	-

See the detail of Patricia Delaite's experience

Training of Patricia Delaite

University of Geneva	Doctorate Degree
University of Lausanne	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Patricia Delaite's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
CANTARGIA AB	Health Technology

Private companies	2
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Health Technology
Nouscom AG Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.	Health Technology